Home > Research > Publications & Outputs > Drug-responsive autism phenotypes in the 16p11....

Electronic data

  • Mitchell et al., 2020

    Final published version, 2.4 MB, PDF document

    Available under license: CC BY: Creative Commons Attribution 4.0 International License


Text available via DOI:

View graph of relations

Drug-responsive autism phenotypes in the 16p11.2 deletion mouse model: a central role for gene-environment interactions

Research output: Contribution to Journal/MagazineJournal articlepeer-review

  • Emma J Mitchell
  • David M Thomson
  • Rebecca L Openshaw
  • Greg C. Bristow
  • Neil Dawson
  • Judith A Pratt
  • Brian J Morris
Article number12303
<mark>Journal publication date</mark>23/07/2020
<mark>Journal</mark>Scientific Reports
Issue number1
Number of pages11
Publication StatusPublished
<mark>Original language</mark>English


There are no current treatments for autism, despite its high prevalence. Deletions of chromosome 16p11.2 dramatically increase risk for autism, suggesting that mice with an equivalent genetic rearrangement may offer a valuable model for the testing of novel classes of therapeutic drug. 16p11.2 deletion (16p11.2 DEL) mice and wild-type controls were assessed using an ethological approach, with 24 h monitoring of activity and social interaction of groups of mice in a home-cage environment. The ability of the excitation/inhibition modulator N-acetyl cysteine (NAC) and the 5-HT1B/1D/1F receptor agonist eletriptan to normalise the behavioural deficits observed was tested. 16p11.2 DEL mice exhibited largely normal behaviours, but, following the stress of an injection, showed hyperlocomotion, reduced sociability, and a strong anxiolytic phenotype. The hyperactivity and reduced sociability, but not the suppressed anxiety, were effectively attenuated by both NAC and eletriptan. The data suggest that 16p11.2 DEL mice show an autism-relevant phenotype that becomes overt after an acute stressor, emphasising the importance of gene-environmental interactions in phenotypic analysis. Further, they add to an emerging view that NAC, or 5-HT1B/1D/1F receptor agonist treatment, may be a promising strategy for further investigation as a future treatment.